Patents by Inventor Nishimura Osamu

Nishimura Osamu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of producing a 19P2 ligand
    Patent number: 6258561
    Abstract: The method of the present invention is suitable for the commercial high-level production of a protein or peptide which can be used as a prophylactic and therapeutic drug for various diseases such as senile dementia, cerebrovascular dementia (dementia arising from cerebrovascular disorders), dementia associated with genealogical retroplastic diseases (e.g. Alzheimer's disease, Parkinson's disease, Pick's disease, Huntington's disease, etc.), dementia associated with infectious diseases (e.g. Creutzfeldt-Jakob's and other virus diseases), dementia associated with endocrine or metabolic disease or toxicosis (e.g. hypothyroidism, vitamin B12 deficiency, alcoholism, intoxication by drugs, metals, and organic compounds), dementia associated with tumorigenic diseases (e.g. brain tumor), dementia associated with traumatic diseases (e.g.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: July 10, 2001
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Suenaga Masato, Moriya Takeo, Tanaka Yoko, Nishimura Osamu
  • Method of producing a 19P2 ligand
    Patent number: 6103882
    Abstract: The method of the present invention is suitable for the commercial high-level production of a protein or peptide which can be used as a prophylactic and therapeutic drug for various diseases such as senile dementia, cerebrovascular dementia (dementia arising from cerebrovascular disorders), dementia associated with genealogical retroplastic diseases (e.g. Alzheimer's disease, Parkinson's disease, Pick's disease, Huntington's disease, etc.), dementia associated with infectious diseases (e.g. Creutzfeldt-Jakob's and other virus diseases), dementia associated with endocrine or metabolic disease or toxicosis (e.g. hypothyroidism, vitamin B12 deficiency, alcoholism, intoxication by drugs, metals, and organic compounds), dementia associated with tumorigenic diseases (e.g. brain tumor), dementia associated with traumatic diseases (e.g. chronic subarachnoidal hemorrhage), and other types of dementia, depression, hyperactive child syndrome (microencephalopathy), and disturbance of consciousness.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: August 15, 2000
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Suenaga Masato, Moriya Takeo, Tanaka Yoko, Nishimura Osamu
  • Modified hepatitis B virus surface antigen P31 and production thereof
    Patent number: 5164485
    Abstract: A modified protein (i) derived from a hepatitis B virus surface antigen P31 protein and (ii) having hepatitis B virus surface antigen activity and the ability to bind polymerized human serum albumin, wherein the modification comprises rendering at least one trypsin-like protease sensitive site of the hepatitis B virus surface antigen P31 protein insensitive. The modified protein can be used in the production of a vaccine for prevention of hepatitis B virus infections and as an antigen for diagnosis of hepatitis B virus infections.
    Type: Grant
    Filed: July 3, 1990
    Date of Patent: November 17, 1992
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Fujisawa Yukio, Itoh Yasuaki, Nishimura Osamu, Fujii Tomoko
  • DNA sequence encoding modified hepatitis B virus surface antigen P31 protein
    Patent number: 4983520
    Abstract: A modified protein (i) derived from a hepatitis B virus surface antigen P31 protein and (ii) having hepatitis B virus surface antigen activity and the ability to bind polymerized human serum albumin, wherein the modification comprises rendering at least one trypsin-like protease sensitive site of the hepatitis B virus surface antigen P31 protein insensitive. The modified protein can be used in the production of a vaccine for prevention of hepatitis B virus infections and as an antigen for diagnosis of hepatitis B virus infections.
    Type: Grant
    Filed: August 20, 1986
    Date of Patent: January 8, 1991
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Fujisawa Yukio, Itoh Yasuaki, Nishimura Osamu, Fujii Tomoko